<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170166</url>
  </required_header>
  <id_info>
    <org_study_id>249246</org_study_id>
    <nct_id>NCT04170166</nct_id>
  </id_info>
  <brief_title>Subacromial Injections for Shoulder Subacromial Pain Syndrome - Anterolateral vs Posterior Approach</brief_title>
  <official_title>Subacromial Injections for Shoulder Subacromial Pain Syndrome - Comparing Anterolateral Versus Posterior Approach: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blackpool Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blackpool Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if there is any difference in terms of pain relief in patients
      with shoulder subacromial pain syndrome, when given a steroid injection into the subacromial
      space via an anterolateral approach compared to a posterior approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who present with subacromial pain syndrome (disorders such as subacromial bursitis,
      rotator cuff tendinopathy, calcific tendinitis, subacromial inflammation with a partial
      thickness rotator cuff tear) to the orthopaedic outpatient clinic are treated initially with
      a subacromial steroid injection in addition to physiotherapy for a period of 3 months. This
      applies to patients who have had no other treatments previously as well as to patients who
      have had previous physiotherapy or steroid injections prior to presentation. Patients who do
      not want to undergo the treatment offered are either treated with simple analgesia, sole
      physiotherapy or surgery.

      When a patient with one of the above conditions agrees to go ahead with a steroid injection
      followed by physiotherapy, the steroid injection is given at the earliest opportunity. The
      steroid injection is given into the subacromial space either using the anterolateral
      (front-side) approach (1 cm below and behind the anterior edge of the acromion with the
      needle aiming towards the under surface of the acromion) or using the posterior (back-side)
      approach ( 1cm inferior and medial to the posterlateral acromial edge with the needle
      pointing towards the anterolateral aspect of the acromion). The exact approach is determined
      according to the preference of the person carrying out the injection. As a routine we use a
      10ml syringe containing 10mls of 0.25% Marcaine along with 40mg triamcinolone with an 18
      gauge (green) needle. It is normal for patients to complain of some discomfort during the
      injection. If a patient experiences any significant discomfort or they cannot tolerate the
      injection for whatever reason, then the injection is discontinued and is not reattempted
      using a different approach.

      Following the injection, patients are questioned on any discomfort experienced during the
      injection and on whether or not their pain has improved. They are then taken through a
      protocol of physiotherapy for their shoulder over the subsequent 3 months. A protocol is
      issued for guidance however therapists are allowed to use other modalities as per their
      discretion. The frequency of appointments with physiotherapy will depend on patient's
      symptoms as well as their progression. For study purposes a frequency record of these
      meetings will be kept and matched to the overall OSS. Patients are seen routinely in 3 months
      following an injection in order to assess any improvement in symptomatology using the OSS,
      visual analogue score, DASH and SF36 questionaires. If the symptoms have improved then no
      further intervention is taken. Further OSS, visual analogue pain score, DASH and SF36
      questionaires will be posted out at 6 months and 1 year. On the other hand, if they are still
      troubled with symptoms then the possibility of further injections or surgery is discussed.

      The aim of this study is to compare the two approaches that are currently used for
      subacromial steroid injections, namely the anterolateral and posterior approach, with regards
      to their effectiveness in improving shoulder symptoms. There will be no deviation from our
      routine protocol other than randomising patients who agree to participate in this study to
      either the anterolateral or posterior approach.

      In summary, it is patients who are seen in clinic with a subacromial pathology and
      subsequently diagnosed with shoulder subacromial pain syndrome, who are offered an injection.
      Those who agree to have an injection will then be invited to participate in the study. An
      information leaflet will be given to all potential participants and they will be allowed
      sufficient time to read through it, digest all the information and ask any questions they may
      have before making a decision regarding their participation. Those who agree to participate
      will be randomly allocated, using sealed envelopes to one of the two approaches for the
      injection. The injection will then be administered via the selected approach by a clinician
      who is qualified in carrying out the procedure. Patients will be asked about any discomfort
      experienced during the injection, improvement in pain following the injection prior to
      leaving hospital and overall satisfaction with the injection. Following this patients will
      have physiotherapy as an outpatient as routine and will be seen at about 3 months post
      injection for a further assessment at the clinic. Again the shoulder assessment will be
      repeated on that occasion. Shoulder assessment questionaires will be posted out for
      completion at 6 months and 1 year (OSS, pain on visial analogue scale, DASH and SF36) There
      will be no change in patients care from routine practice other than the randomisation of the
      approach used for the injection. Patients who are invited to participate in the study and
      agree to participate will have their GP informed of their participation.

      Assessments

        1. Prior to injection: assessment of pain using a visual analogue score, clinical
           assessment of shoulder movement and completion of a modified Oxford Shoulder Score,
           Disabilities of Shoulder, Arm and Hand questionaires and Short Form 36 Health Survey.

        2. 20-30 minutes Post injection: assessment of pain using a visual analogue score

        3. Prior to leaving hospital: pain experienced during the administration of the injection
           and the overall satisfaction with the injection

        4. 3 months post injection: assessment of pain using a visual analogue score, clinical
           assessment of shoulder movement and completion of a modified Oxford Shoulder Score,
           Disabilities of Shoulder, Arm and Hand questionaires and Short Form 36 Health Survey.

        5. 6 months and 1 year post injection: assessment of pain using visual analogue score and
           completion of a modified Oxford Shoulder Score, Disabilities of Shoulder, Arm and Hand
           questionaires and Short Form 36 Health Survey via post.

      The main outcome for this study will be the Oxford Shoulder Score (OSS) at 3 months
      post-injection. In addition to the standard OSS, the questionnaire will inquire about general
      symptoms and signs, duration, hand dominance, previous injuries to the shoulder and previous
      treatments to the shoulder. The follow up questionnaire will be identical to the initial
      questionnaire but excluding questions on previous treatments, hand dominance, injuries and
      duration.

      Other demographics that will be recorded on the pre-designed pro forma include: number and
      frequency of physiotherapy sessions pre and post injection, and subsequent need for further
      management.

      Hard copies of data (questionnaires and forms) collected will be placed into the patient's
      notes. At the same time this data will be recorded electronically on an Excel database and
      saved on an encrypted, password protected memory stick. This memory stick will be stored in a
      locked filing cabinet in the orthopaedic department at Blackpool Victoria Hospital. Please
      note: The electronic data will contain NO identifiable information. Participants will be
      identified by a unique study I.D number which can only be linked to them by members of the
      research team.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxford Shoulder Score</measure>
    <time_frame>3 months</time_frame>
    <description>The primary outcome measure will be the change in the Oxford Shoulder Score at 3 months post injection. Scores range from 0-48 with 48 being the best possible outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxford Shoulder Score</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Change in the Oxford Shoulder Score at 6 months and 1 year post injection. Scores range from 0-48 with 48 being the best possible outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on visual analogue scale</measure>
    <time_frame>3 months, 6 months and 1 year post injection</time_frame>
    <description>Change in pain on the visual analogue scale at 3 months, 6 months and 1 year post injection. As this is a visual analogue scale this is a visual scale with no numeric values attached however on the left side of the scale will be no pain and the right side will be maximal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disabilities of Arm, Shoulder and Hand Questionnaire</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Change in the Disabilities of Arm, Shoulder and Hand Questionnaire score at 3 months, 6 months and 1 year post injection. This is a score that ranges from 0-100 with 0 meaning no disability and 100 meaning most severe disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 Health Survey Score</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Change in the Short From 36 Health Survey Score at 3 months, 6 months and 1 year post injection. This is a range from 0-100 with the higher the score, the less disability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Shoulder Subacromial Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Anterolateral Approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The randomised group of patients receiving the subacromial steroid injection via an anterolateral approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posterior Approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The randomised group of patients receiving the subacromial steroid injection via a posterior approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anterolateral subacromial steroid injection</intervention_name>
    <description>Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach</description>
    <arm_group_label>Anterolateral Approach</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Posterior subacromial steroid injection</intervention_name>
    <description>Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach</description>
    <arm_group_label>Posterior Approach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient diagnosed with shoulder subacromial pain syndrome

          -  Age â‰¥ 18

          -  Capacity to give valid consent for participation

          -  Able to complete the follow up

        Exclusion Criteria:

          -  Age &lt; 18

          -  Lacking capacity/unable to give valid consent for participation

          -  Full thickness rotator cuff tear diagnosed on either Ultrasound scan or Magnestic
             Resonance Imaging

          -  Unable to complete follow up

          -  Unable to speak or read English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charalambos Charalambous</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant Orthopaedic Surgeon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen Morgan</last_name>
    <phone>+441253955453</phone>
    <email>maureen.morgan1@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Maureen Morgan</last_name>
      <phone>+441253955453</phone>
      <email>maureen.morgan1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Charalambos Charalambous</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John T Hirst</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blackpool Teaching Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Charalambos Charalambous</investigator_full_name>
    <investigator_title>Consultant Orthopaedic Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT04170166/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

